StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer All Other Oncology by Quarter

All Other Oncology — Worldwide operational (constant-currency) YoY (%) (%)

QuarterlyAnnual

Pfizer All Other Oncology: -16.0% in Q2 2026, down 26.0 pts from a year earlier. That is the lowest of the 28 quarters on record here.

Latest, Q2 2026
-16.0%
Period ended Jun 28, 2026
Change on a year earlier
-26.0 pts
10.0% in Q2 2025
History
28 quarters
Since Q4 2018
Sources
28
Documents cited below

Where the Q2 2026 figure comes from

“|| All other Oncology | 338 | 394 | (14%) | (16%) | 178 | 141 | 27% | 159 | 253 | (37%) | (40%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAll Other Oncology — Worldwide operational (constant-currency) YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 2026-16.0%-26.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 2026-3.0%-20.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 20255.0%-2.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q2 2025Jun 29, 202510.0%+7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202517.0%+30.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2024Dec 31, 20247.0%-7.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2024Sep 29, 202415.0%-25.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2024Jun 30, 20243.0%-23.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-13.0%-29.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2023Dec 31, 202314.0%-29.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2023Oct 1, 202340.0%-12.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗
Q2 2023Jul 2, 202326.0%-14.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07022023xex99.htm, filed 2023-08-01) ↗
Q1 2023Apr 2, 202316.0%–Form 8-K (Earnings / Guidance Release) (pfe-04022023xex99.htm, filed 2023-05-02) ↗
Q4 2022Dec 31, 202243.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
Q3 2022Oct 2, 202252.0%+13.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-10022022xex99.htm, filed 2022-11-01) ↗
Q2 2022Jul 3, 202240.0%-54.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-07032022xex99.htm, filed 2022-07-28) ↗

Cite this data

StockData. (2026). Pfizer All Other Oncology (%), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/other-onc-oper-ww

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.